CellSeedCellSeed Inc.7776東証グロース精密機器FY ending Dec 2025, non-consolidated, J-GAAP

CellSeed FY ending Dec 2019 results

About 58% of CellSeed's sales come from Cell-Sheet regenerative medicine, with Laboratory consumables and equipment making up much of the rest.

It lost about ¥283 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 CellSeed sells, how much goes where, and how much is kept.

FY ending Dec 2019
Cost of sales
¥21
SG&A
¥362
Operating loss
¥283
Net loss
¥284

Margin funnel (derived from reported values)Gross margin 78.5% → Operating margin -283.1% → Net margin -283.7%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2019

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (2)
  • EDINET (FSA Japan)

    有価証券報告書-第21期(令和3年1月1日-令和3年12月31日)

    ID S100NR3A2022-03-28Open
  • EDINET (FSA Japan)

    有価証券報告書-第20期(令和2年1月1日-令和2年12月31日)

    ID S100L1WE2021-03-29Open

Extracted from XBRL: 36 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.